Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.

S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>

Science

Health & Fitness

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

Sign up to save your podcasts

S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

More shows like OncLive® On Air

Wait Wait... Don't Tell Me!

Marketplace Morning Report

Marketplace

Research To Practice | Oncology Videos

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

JAMA Clinical Reviews

ASCO Daily News

The Curbsiders Internal Medicine Podcast

OncoPharm

ASCO Guidelines

Lung Cancer Considered

Oncology Today with Dr Neil Love

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions

NEJM AI Grand Rounds